-
-
-
The Expanding Benefits of GLP-1 Medicines
Diabetes
Discover the expanding benefits of GLP-1 drugs beyond diabetes and obesity, including improvements in heart, kidney, liver, joint, brain health, and more, as summarized by GLP-1 pioneer Daniel J. Drucker.
-
EU Confirms Vision Risk Tied to Semaglutide
EMA
EU regulators have confirmed a rare risk of vision loss linked to Novo Nordisk’s semaglutide, used in Wegovy and Ozempic. Drug labels will be updated to reflect the potential for NAION, a serious but very rare eye condition.
-
-
Top 10 Best-Selling Drugs in Q1 2025
Market Trend
Discover the top 10 best-selling drugs of Q1 2025. GLP-1 drugs dominate, with semaglutide and tirzepatide leading growth. Oncology and autoimmune treatments face challenges amid rising competition and patent expirations.
-
-
-
-
中阳县|
开原市|
峨眉山市|
古丈县|
沭阳县|
江孜县|
江西省|
靖宇县|
天全县|
漠河县|
义马市|
镇雄县|
呼和浩特市|
玉田县|
济南市|
得荣县|
疏附县|
包头市|
乌兰察布市|
崇阳县|
德阳市|
民乐县|
图木舒克市|
漠河县|
龙江县|
临泉县|
闽清县|
宁德市|
烟台市|
定南县|
泗阳县|
汪清县|
翼城县|
香港
|
嘉峪关市|
喀喇沁旗|
沭阳县|
安吉县|
汪清县|
永和县|
正定县|